Showing 2811-2820 of 3242 results for "".
- Valeant Dermatology Launches Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/valeant-dermatology-launches-aspire-higher-scholarship-program/2458676/Valeant Dermatology, a division of Valeant Pharmaceuticals North America LLC, launched Valeant Dermatology ASPIRE HIGHER Scholarship Program that will award scholarships of up to $10,000 each to nine individual students who will be attending an undergraduate or graduate education program during t
- WHO: Improved Access to Psoriasis Treatments Neededhttps://practicaldermatology.com/news/who-improved-access-to-psoriasis-treatments-needed/2458685/Key stakeholders including policy makers, physicians and patients must come together to turn the corner on psoriasis, according to the World Health Organization’s (WHO) new Globa
- NOVAN: First Patient Dosed in Phase 3 Program for SB204https://practicaldermatology.com/news/novan-first-patient-dosed-in-phase-3-program-for-sb204/2458688/The first patient has been dosed in a Phase 3 study of Novan’s investigational topical nitric oxide acne gel, Novan, Inc. reports. Novan is running two identically designed Phase 3 pivotal trials in parallel to evaluate the effic
- Tempted by Temptu to Debut at AAD Annual Meetinghttps://practicaldermatology.com/news/tempted-by-temptu-to-debut-at-aad-annual-meeting/2458691/At the upcoming 2016 AAD annual meeting, TEMPTU introduces its groundbreaking TEMPTU Air, the first handheld airbrush makeup device for skin perfection. Using the company’s patented Airpod and Atomized AirFlow™ Technology, TEMPTU Air delivers a micro-fine mist that floa
- Endo International Launches New Phase 2b Study of CCH for Cellulitehttps://practicaldermatology.com/news/endo-international-launches-new-phase-2b-study-of-cch-for-cellulite/2458699/A Phase 2b study of collagenase clostridium histolyticum (CCH) for the treatment of as cellulite is about to get started, Endo International plc reports. CCH is intended to target and lyse collagen tethers with the goal of releasing the skin di
- Caladrius Biosciences Licenses Dermatology Cell Technology to AiVita Biomedicalhttps://practicaldermatology.com/news/caladrius-biosciences-licenses-dermatology-cell-technology-to-aivita-biomedical/2458698/Caladrius Biosciences, Inc., has licensed exclusive global rights to its cell-derived dermatological technology for topical skin applications to AiVita Biomedical, Inc. The company says this transaction supports its strategy to monetize non-core assets. AiVita, a biotechnology company, wa
- Phase 3 Data for BF-200 ALA Presented at the 14th South Beach Symposiumhttps://practicaldermatology.com/news/phase-3-data-for-bf-200-ala-presented-at-the-14th-south-beach-symposium/2458702/Biofrontera AG’s BF-200 ALA plus red light photodynamic therapy (PDT) shows good efficacy for the treatment of actinic keratoses (AK), according to data presented from three pivotal Phase III trials at the 14th Annual South Beach Symposium. The results were presented in a poster (Poster #11
- ZELTIQ® Taps Todd Zavodnick as New President, Internationalhttps://practicaldermatology.com/news/zeltiq-taps-todd-zavodnick-as-new-president-international/2458708/Todd Zavodnick is the new President, International of ZELTIQ®. Mr. Zavodnick will be responsible for driving the company’s international growth and expansion. He rec
- Traffic-related Air pollution Linked to Facial Lentigeneshttps://practicaldermatology.com/news/traffic-related-air-pollution-linked-to-facial-lentigenes/2458707/High levels of traffic-related air pollution and air pollution-associated gases may increase risk of developing facial lentigenes, new research suggests. "While NO2 exposure is known to be associated with low lung function and lung cancer, the effect o
- Otsuka Licenses Pre-Phase 3 Topical Atopic Dermatitis Treatment to Medimetrikshttps://practicaldermatology.com/news/otsuka-licenses-pre-phase-3-topical-atopic-dermatitis-treatment-to-medimetriks/2458712/Otsuka Pharmaceutical Co., Ltd. and Medimetriks Pharmaceuticals, Inc. have entered into a licensing agreement granting Medimetriks exclusive development, manufacturing and commercialization rights for OPA-15406 in